---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-154729"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:20:15.500147+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coya gets $3.85M from Dr. Reddy's for COYA 302 Phase 2 trial; first $6M royalties waived

## Summary
- Dr. Reddy's makes $3.85M one-time payment to Coya for funding first Phase 2 trial of COYA 302 in ALS.
- Dr. Reddy's has no obligation to pay the first $6M in royalties otherwise due under the DRL Development Agreement.
- Amendment effective June 4, 2024; payment due within 5 business days of Coya's invoice.
- Funds must be used solely for the Phase 2 trial in the U.S. as per the Development Plan.

## SEC filing metadata
- accession: 0001193125-24-154729
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312524154729/0001193125-24-154729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312524154729/d838051d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-154729
- JSON: https://secwatch.observer/filing/0001193125-24-154729.json
- Plain text: https://secwatch.observer/filing/0001193125-24-154729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.